USP appoints regulatory experts to elemental impurities implementation advisory group.

One employee is dismissed, another has resigned, and three others are put on administrative leave.

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.

The multimillion-dollar deal focuses oncology.

EMA's revised guideline on biosimilars containing biotechnology-derived proteins is published for public consultation.

FDA cites cGMP violations of finished pharmaceuticals at the company's facilities in Marion North Carolina and Jayuya, Puerto Rico.

Facility will use mammalian cell-culture technology and be ready for operations by 2016.

Agreement seeks to advance novel drug targets and focus on therapies for ulcerative colitis.

Acquisition will strengthen AstraZeneca's respiratory portfolio with a potential new treatment for chronic obstructive pulmonary disease.

Modular containment room at Belfast facility allows studies of biologics and vaccines.

The company is cited for using unapproved visual-inspection methods for finished parenteral drugs and conducting inadequate visual inspections.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Highlights from the 66th World Health Assembly and the pharmaceutical industry?s role in addressing noncommunicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, the global vaccine action plan, and neglected tropical diseases.

The agreement is worth up to $552 million, depending on meeting set milestones.

Pfizer had gained the facility through its previous acquisition of King Pharmaceuticals.

-

Unither Pharmaceuticals will acquire an UCB Rochester, NY pharmaceutical plant used to liquid pharmaceutical products.

A new panel will create reports that assess changes in the pharmaceutical industry.

The companies cancel plans to develop and manufacture generic drugs in Japan.

A unique demographic and payer mix make ASEAN an increasingly attractive region.

With downsizing occurring more frequently than ever within the pharmaceutical industry, is Europe doing enough to curb further job losses that could threaten the recovery of its economy?

Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.

Crushing, fracturing, and bending tests quantify hardness.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

GSK expands its vaccines platform technology expertise by acquiring Okairos, a Swiss-based company.

Competence in process safety is important for preventing accidents.

FDA addresses shortages of drugs needed to treat premature infants and patients unable to eat or drink by mouth.

Cloud-computing solutions and software enable researchers to garner insight from large, public-health datasets.